TGA quarantines contaminated human albumin from CSL
09 March, 2012 by Tim DeanHuman albumin manufactured by CSL has been quarantined by the Therapeutic Goods Administration due to fears it may be contaminated with ethylene glycol.
Osprey Medical to raise $20m in IPO
08 March, 2012 by Dylan Bushell-EmblingOsprey Medical, a US-headquartered medical device company developing products based on Australian research, plans to list on the ASX via a $20m IPO.
Latest AusBiotech journal features special medtech edition
08 March, 2012 by AusBiotechAusBiotech is pleased to announce that the first edition for 2012 (March issue) of AusBiotech’s journal, Australasian Biotechnology, is now published, featuring a special medical technology edition.
Minomic gets $5m investment funding
08 March, 2012 by Dylan Bushell-EmblingThe Carnegie Innovation Fund has committed to invest up to $5 million in NSW-based prostate cancer diagnostic company Minomic International.
Bionomics gains after All Ordinaries rebalance
08 March, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) shares grew 12.4% in two days after Standard & Poor's added the company to the S&P All Ordinaries index during its latest rebalance.
Last chance to catch this year’s BD Forum… in Queensland
06 March, 2012 by AusBiotechAusBiotech has announced the final chance for biotech business development professionals to attend the annual dedicated Business Development Forum and Workshop (BD Forum) in Queensland.
Phosphagenics signs deal in Japan
05 March, 2012 by Dylan Bushell-EmblingJapan's Nippon Zoki Pharmaceutical has agreed to assess Phosphagenics' (ASX:POH) TPM/diclofenac pain patch for its suitability in the Japan and US markets.
ACPFG, DuPont expand agbiotech research deal
02 March, 2012 by Dylan Bushell-EmblingDuPont subsidiary Pioneer Hi-Breed and agricultural research body ACPFG have expanded a longstanding agreement to collaborate on agricultural biotechnology R&D.
Join the 2012 business delegation to BIO
01 March, 2012 by AusBiotechAusBiotech invites you to take part in the BIO International Convention, the largest global event for the biotechnology industry, attracting the biggest names in biotech.
Sirtex Medical 1H profit climbs 70%
01 March, 2012 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has reported a 69.7% increase in 1H profit, due in part to accelerating sales of its radioactive microsphere treatments for liver cancer.
Alchemia granted new US fondaparinux patent
01 March, 2012 by Dylan Bushell-EmblingAlchemia Limited (ASX:ACL) has been granted the second of four US patents it has applied for to protect its manufacturing process for the fondaparinux blood clot treatment.
LCT posts $8.1m 1H profit on JV deal
01 March, 2012 by Dylan Bushell-EmblingLiving Cell Technologies (ASX:LCT) swung to an $8.1m profit in 1H12, after selling its DIABECELL assets to its new 50/50 joint venture.
Genetic Technologies reports $3.3m 1H loss
29 February, 2012 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has reported a $3.3m loss for 1H12, as a result of declining diagnostics and patent licensing revenue.
Coridon developing next-gen HPV vaccine
29 February, 2012 by Dylan Bushell-EmblingIan Frazer and the team at Coridon is working on a new vaccine that will also provide treatment for human papillomavirus (HPV) in infected women.
Patent reform bill passes Senate
28 February, 2012 by Tim DeanThe Raising the Bar bill, which tightens Australian patent laws, including adding an exemption for researchers, has cleared the Senate and will move to the House of Representatives.
